Actively Recruiting
Study of PF-08634404 Alone and With Ipilimumab for Adults With Advanced or Metastatic Hepatocellular Carcinoma Not Suitable for Surgery
Led by Pfizer · Updated on 2026-10-08
138
Participants Needed
60
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of a study medicine called PF-08634404, given alone or combined with another antibody named ipilimumab, in adults with a type of liver cancer called hepatocellular carcinoma HCC that is locally advanced or has spread to other parts of the body. This study focuses on patients whose cancer cannot be removed by surgery and who have not yet received whole-body treatment for HCC. Participants will receive PF-08634404 either as a single treatment or together with ipilimumab. Both medicines will be given through intravenous IV infusions administered directly into a vein at clinical trial sites. Participants are randomly assigned to receive either the study medicine alone or in combination with the antibody, with dose levels given sequentially. During the study, participants will be monitored for safety and response to treatment, including adverse events and tumor response using standard criteria. Researchers will assess overall response rates, progression-free survival, and other health measures over approximately 24 months. Medical staff will also track blood tests, serum drug levels, and immune responses. Treatment and follow-up visits will include clinical assessments to understand the effects and side effects of these therapies.
CONDITIONS
Brief Title
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here